Oxaliplatin in the treatment of colorectal cancer

George P. Kim, Charles Erlichman

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Significant advances in the treatment of colorectal cancer have been observed over the past several years. With the introduction of oxaliplatin combined with infusional 5-fluorouracil and leucovorin, survival for patients with metastatic colorectal cancer has nearly doubled. The incorporation of biologic agents that target angiogenesis (bevacizumab) and tumor growth pathways (cetuximab, panitumimab) extends survival even further, in addition to increasing response rates in patients with metastatic disease. The benefit of these newer drugs is also being realized in the adjuvant setting, where the addition of oxaliplatin to infusional 5-fluorouracil and leucovorin has led to improvements in 3-year disease-free survival. Future challenges with the use of oxaliplatin include defining strategies to optimize its use while avoiding treatment-limiting neurotoxicity and identification of markers predictive of response.

Original languageEnglish (US)
Pages (from-to)281-294
Number of pages14
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume3
Issue number2
DOIs
StatePublished - Apr 2007

Fingerprint

oxaliplatin
Colorectal Neoplasms
Leucovorin
Fluorouracil
Survival
Biological Factors
Disease-Free Survival
Tumors
Therapeutics
Growth
Pharmaceutical Preparations
Neoplasms

Keywords

  • Action potential
  • Antibody
  • Antineoplastic agent
  • Camptothecin
  • Colorectal neoplasm
  • DNA repair
  • Fluorouracil
  • Glutathione S-transferase
  • Hepatic veno-occlusive disease
  • Monoclonal nerve fiber
  • Organoplatinum compound
  • Polymorphism
  • Survival analysis

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Oxaliplatin in the treatment of colorectal cancer. / Kim, George P.; Erlichman, Charles.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 3, No. 2, 04.2007, p. 281-294.

Research output: Contribution to journalArticle

Kim, George P. ; Erlichman, Charles. / Oxaliplatin in the treatment of colorectal cancer. In: Expert Opinion on Drug Metabolism and Toxicology. 2007 ; Vol. 3, No. 2. pp. 281-294.
@article{222d89b39d7d41be96ca394e48721241,
title = "Oxaliplatin in the treatment of colorectal cancer",
abstract = "Significant advances in the treatment of colorectal cancer have been observed over the past several years. With the introduction of oxaliplatin combined with infusional 5-fluorouracil and leucovorin, survival for patients with metastatic colorectal cancer has nearly doubled. The incorporation of biologic agents that target angiogenesis (bevacizumab) and tumor growth pathways (cetuximab, panitumimab) extends survival even further, in addition to increasing response rates in patients with metastatic disease. The benefit of these newer drugs is also being realized in the adjuvant setting, where the addition of oxaliplatin to infusional 5-fluorouracil and leucovorin has led to improvements in 3-year disease-free survival. Future challenges with the use of oxaliplatin include defining strategies to optimize its use while avoiding treatment-limiting neurotoxicity and identification of markers predictive of response.",
keywords = "Action potential, Antibody, Antineoplastic agent, Camptothecin, Colorectal neoplasm, DNA repair, Fluorouracil, Glutathione S-transferase, Hepatic veno-occlusive disease, Monoclonal nerve fiber, Organoplatinum compound, Polymorphism, Survival analysis",
author = "Kim, {George P.} and Charles Erlichman",
year = "2007",
month = "4",
doi = "10.1517/17425255.3.2.281",
language = "English (US)",
volume = "3",
pages = "281--294",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Oxaliplatin in the treatment of colorectal cancer

AU - Kim, George P.

AU - Erlichman, Charles

PY - 2007/4

Y1 - 2007/4

N2 - Significant advances in the treatment of colorectal cancer have been observed over the past several years. With the introduction of oxaliplatin combined with infusional 5-fluorouracil and leucovorin, survival for patients with metastatic colorectal cancer has nearly doubled. The incorporation of biologic agents that target angiogenesis (bevacizumab) and tumor growth pathways (cetuximab, panitumimab) extends survival even further, in addition to increasing response rates in patients with metastatic disease. The benefit of these newer drugs is also being realized in the adjuvant setting, where the addition of oxaliplatin to infusional 5-fluorouracil and leucovorin has led to improvements in 3-year disease-free survival. Future challenges with the use of oxaliplatin include defining strategies to optimize its use while avoiding treatment-limiting neurotoxicity and identification of markers predictive of response.

AB - Significant advances in the treatment of colorectal cancer have been observed over the past several years. With the introduction of oxaliplatin combined with infusional 5-fluorouracil and leucovorin, survival for patients with metastatic colorectal cancer has nearly doubled. The incorporation of biologic agents that target angiogenesis (bevacizumab) and tumor growth pathways (cetuximab, panitumimab) extends survival even further, in addition to increasing response rates in patients with metastatic disease. The benefit of these newer drugs is also being realized in the adjuvant setting, where the addition of oxaliplatin to infusional 5-fluorouracil and leucovorin has led to improvements in 3-year disease-free survival. Future challenges with the use of oxaliplatin include defining strategies to optimize its use while avoiding treatment-limiting neurotoxicity and identification of markers predictive of response.

KW - Action potential

KW - Antibody

KW - Antineoplastic agent

KW - Camptothecin

KW - Colorectal neoplasm

KW - DNA repair

KW - Fluorouracil

KW - Glutathione S-transferase

KW - Hepatic veno-occlusive disease

KW - Monoclonal nerve fiber

KW - Organoplatinum compound

KW - Polymorphism

KW - Survival analysis

UR - http://www.scopus.com/inward/record.url?scp=34547144802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547144802&partnerID=8YFLogxK

U2 - 10.1517/17425255.3.2.281

DO - 10.1517/17425255.3.2.281

M3 - Article

C2 - 17428157

AN - SCOPUS:34547144802

VL - 3

SP - 281

EP - 294

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 2

ER -